We use cookies to ensure that we give you the best experience on our website. If you continue using our website, we'll assume that you are happy to receive all cookies on the Porterhouse Medical website. Further information on cookies and how to change your settings is available here.


What is ONCOR?

February 2017


In order to leverage the wealth of experience that Porterhouse Medical has gathered over the many years of working in a huge range of oncology disease and therapy areas, we have created a new internal department, known as ‘ONCOR’, to focus predominantly on oncology.

Porterhouse has direct experience of working in oncology disease areas, across multiple therapeutic agents:

  • Acute lymphoblastic leukaemia

  • Acute myeloid leukaemia

  • Breast cancer

  • Chronic myeloid leukaemia

  • Gastrointestinal stromal tumours

  • Head and neck cancer

  • Hepatocellular carcinoma

  • Hypercalcaemia of malignancy

  • Melanoma

  • Multiple myeloma

  • Myelodysplastic syndrome

  • Non–small cell lung cancer

  • Pancreatic neuroendocrine tumours

  • Prostate cancer

  • Renal cell carcinoma

By bringing this experience together in a single team, we believe that we and our clients will benefit from the cross-fertilisation of ideas, approaches and practices that has served us so well over the years.

Please do get in touch if you have any queries regarding the ONCOR team or our services. Call Emma Burgess on +44 118 913 9100 or email emmaburgess@porterhouse.biz.

Our services

Porterhouse develops and delivers a broad spectrum of medical and scientific communications services, including:

  • Medical writing (from primary publications to marketing and training materials)

  • Creative (print and digital solutions)

  • Events (from small advisory boards to national meetings and satellite symposia)

  • Strategy (creative solutions to complex strategic issues)

  • Health economics and market access programmes (in-house expertise to gather and interpret data and present fresh ideas to inspire stakeholder confidence)

Over 85% of our work is global or pan-European, and we are all EFPIA or ABPI trained